ArticleAnnals of intensive care2026
Urinary biomarkers IGFBP7 and TIMP-2 in the ICU: a multicenter prospective study on acute kidney injury outcomes.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is prevalent in critically ill patients, contributing to high morbidity, mortality, and healthcare costs. Early detection and differentiation between transient and persistent AKI are critical for guiding timely interventions. This study evaluates the NephroCheck® score, based on Tissue inhibitor of metalloproteinases-2 (TIMP-2) and Insulin-like growth factor-binding protein 7 (IGFBP7) biomarkers. The primary objective was to assess its ability to predict AKI risk and AKI subtype within the first seven days of Intensive Care Unit (ICU) admission. Secondary objectives included evaluating its association with the need for renal replacement therapy (RRT) and overall ICU outcomes in a heterogeneous critical care population. Methods: This prospective, multicenter observational study included 455 ICU patients from five hospitals in Barcelona, Spain. Biomarker analysis was conducted on urine samples collected at admission, and AKI was classified according to the kidney Disease: Improving Global Outcomes (KDIGO) criteria. Patients were grouped by TIMP-2·IGFBP7 values and AKI subtypes. Data was analyzed using Stata version 18.0 (StataCorp, College Station, TX). Results: AKI occurred in 51% of patients; with 29% transient and 71% persistent. High TIMP-2·IGFBP7 (TIMP-2·IGFBP7 > 2.0) levels were significantly associated with AKI (OR 19.44; 95% CI [2.57-146.5], p = 0.004), persistent AKI (OR 4.3; 95% CI [1.61-11.41], p = 0.003), and RRT requirements (OR 3.93; 95% CI [1.34-11.47], p = 0.012). Patients with high TIMP-2·IGFBP7 had longer ICU stays, more severe AKI, increased RRT duration, and higher mortality rates. TIMP-2·IGFBP7 values correlated positively with ICU and in-hospital mortality and reduced 90-day survival. Conclusion: TIMP-2·IGFBP7 showed modest performance for early AKI detection, identifying RRT requirements and risk stratification in critically ill patients. While moderately effective for predicting outcomes, its role in differentiating transient from persistent AKI remains inconsistent. Further research is warranted to optimize TIMP-2·IGFBP7 guided interventions and explore its application in diverse AKI etiologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.